Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Infants with congenital heart defects have reduced brain volumes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Oral pre‑treatment with thiocyanate (SCN−) protects against myocardial ischaemia–reperfusion injury in rats

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The risk of developing a meningioma during and after pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A novel homozygous GFI1B variant in 2 sisters with thrombocytopenia and severe bleeding tendency

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)

    Research output: Contribution to journalReviewpeer-review

  3. Multiple endocrine neoplasia type 2: A reveiw

    Research output: Contribution to journalReviewpeer-review

View graph of relations

Axillary lymph node status is an important prognostic factor for breast cancer patients and sentinel lymph node biopsy (SLNB) is a less invasive surgical proxy. We examined if consecutively derived molecular subtypes from primary breast cancers provide additional predictive value for SLNB status. 1556 patients with a breast cancer > 10 mm underwent primary surgical procedure including SLNB and tumor specimens were assigned with a transcriptomics-based molecular subtype. 1020 patients had a negative sentinel node (SN) and 536 a positive. A significant association between tumor size and SN status (p < 0.0001) was found across all samples, but no association between size and SN status (p = 0.14) was found for BasL tumors. A BasL subtype was a predictor of an SN-negative status (p = 0.001, OR 0.58, 95% CI 0.38;0.90) and among the BasL, postmenopausal status was a predictor for SN-negative status (p = 0.01). Overall survival was significantly lower (p = 0.02) in patients with BasL tumors and a positive SN. Interestingly, we identified a significant correlation between hormone receptor activity and SN status within the BasL subtype. Taken together, molecular subtypes and hormone receptor activity of breast cancers add predictive value for SLNB status.

Original languageEnglish
Article number2259
JournalScientific Reports
Volume11
Issue number1
Pages (from-to)2259
ISSN2045-2322
DOIs
Publication statusPublished - 26 Jan 2021

ID: 66207053